HK94096A - The use of certain calcium-citrate-malate for the manufacture of a medicament for the treatment of osteoporosis - Google Patents

The use of certain calcium-citrate-malate for the manufacture of a medicament for the treatment of osteoporosis Download PDF

Info

Publication number
HK94096A
HK94096A HK94096A HK94096A HK94096A HK 94096 A HK94096 A HK 94096A HK 94096 A HK94096 A HK 94096A HK 94096 A HK94096 A HK 94096A HK 94096 A HK94096 A HK 94096A
Authority
HK
Hong Kong
Prior art keywords
calcium
malate
calcium citrate
citrate
osteoporosis
Prior art date
Application number
HK94096A
Other languages
German (de)
English (en)
Inventor
Ann Kochanowski Barbara
Original Assignee
Norwich Eaton Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norwich Eaton Pharmaceuticals, Inc. filed Critical Norwich Eaton Pharmaceuticals, Inc.
Publication of HK94096A publication Critical patent/HK94096A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A23L33/165—Complexes or chelates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Claims (8)

  1. Utilisation de citrate et malate de calcium pour préparer un médicament destiné au traitement de l'ostéoporose, dans laquelle ledit citrate et malate de calcium présente une proportion molaire du citrate au malate de 1:0,5 à 1:4,5.
  2. Utilisation selon la revendication 1, dans laquelle ledit citrate et malate de calcium présente une proportion molaire du citrate au malate de 1:0,75 à 1:3.
  3. Utilisation selon la revendication 1, dans laquelle ledit citrate et malate de calcium présente une proportion molaire du calcium au total du citrate et du malate de 1:0,7 à 1:0,9.
  4. Utilisation selon la revendication 3, dans laquelle le nombre d'équivalents de calcium dans ledit citrate et malate de calcium est égal au nombre total d'équivalents de citrate augmenté du nombre d'équivalents de malate dans ledit citrate et malate de calcium.
  5. Utilisation selon l'une quelconque des revendications précédentes, dans laquelle ledit médicament contenant du citrate et malate de calcium se présente sous une forme posologique solide.
  6. Utilisation selon l'une quelconque des revendications précédentes, dans laquelle ledit médicament contenant du citrate et malate de calcium se présente sous une forme posologique liquide.
  7. Utilisation selon la revendication 6, dans laquelle ladite forme posologique liquide est une boisson contenant un jus de fruits.
  8. Utilisation selon l'une quelconque des revendications précédentes, dans laquelle ledit médicament se présente sous la forme d'une dose unitaire comprenant de 100 à 1000 mg de citrate et malate de calcium.
HK94096A 1987-08-28 1996-05-30 The use of certain calcium-citrate-malate for the manufacture of a medicament for the treatment of osteoporosis HK94096A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9100687A 1987-08-28 1987-08-28

Publications (1)

Publication Number Publication Date
HK94096A true HK94096A (en) 1996-06-07

Family

ID=22225323

Family Applications (1)

Application Number Title Priority Date Filing Date
HK94096A HK94096A (en) 1987-08-28 1996-05-30 The use of certain calcium-citrate-malate for the manufacture of a medicament for the treatment of osteoporosis

Country Status (9)

Country Link
EP (1) EP0304986B1 (fr)
JP (1) JP2738541B2 (fr)
KR (1) KR970009582B1 (fr)
AT (1) ATE88633T1 (fr)
CA (1) CA1329774C (fr)
DE (1) DE3880587T2 (fr)
HK (1) HK94096A (fr)
IE (1) IE61451B1 (fr)
PH (1) PH25585A (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108761A (en) * 1990-10-01 1992-04-28 The Procter & Gamble Company Method of preventing tooth enamel erosion utilizing an acidic beverage containing calcium
JPH06502310A (ja) * 1990-10-31 1994-03-17 ザ、プロクター、エンド、ギャンブル、カンパニー カルシウム強化ソース
WO1993012672A1 (fr) * 1991-12-26 1993-07-08 The Procter & Gamble Company Concentres pour boissons enrichis en calcium et stables en stockage
US5389387A (en) * 1991-12-26 1995-02-14 The Procter & Gamble Company Storage stable calcium-supplemented beverage concentrates
AU4597293A (en) * 1992-06-30 1994-01-24 Procter & Gamble Company, The Effervescent calcium supplements
WO1994008472A1 (fr) * 1992-10-21 1994-04-28 The Procter & Gamble Company Source de calcium biodisponible concentre
ATE140125T1 (de) * 1992-10-21 1996-07-15 Procter & Gamble Lagerfähige, kalziumzusatzenthaltende getränkekonzentrate und sirup
EP0665719B1 (fr) * 1992-10-21 1997-01-15 The Procter & Gamble Company Edulcorant contenant une source de calcium biodisponible concentre
IT1256300B (it) * 1992-11-05 1995-11-29 Dompe Farmaceutici Spa Uso di acidi aril-, eteroaril- e alchiltartronici come agenti terapeutici
BR9914079A (pt) * 1998-09-29 2001-06-19 Procter & Gamble Bebidas de baixa acidez suplementadas com fontes de cálcio nutricionais
US6811800B2 (en) 1998-09-29 2004-11-02 The Procter & Gamble Co. Calcium fortified beverages
CN101505730B (zh) * 2006-08-17 2013-02-13 宝洁公司 包含柠檬酸苹果酸钙的组合物以及它们的制备方法
TR200908237A2 (tr) 2009-11-02 2011-05-23 Bi̇lgi̇ç Mahmut Kalsiyum ve D vitamini içeren farmasötik bileşimler.
EP2685973A1 (fr) 2011-03-16 2014-01-22 The Charlotte-Mecklenburg Hospital Authority D/B/A Compositions et procédés pour le traitement de maladies et de troubles de type musculosquelettiques au moyen de complexes ion métallique-analogue de citrate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5697248A (en) * 1979-12-28 1981-08-05 Tanaka Shiro Conjugated compound of calcium citrate and calcium malate and its preparation
FR2601249A1 (fr) * 1986-07-09 1988-01-15 Sandoz Lab Nouvelles compositions pharmaceutiques a base de sels de calcium.
US4786510A (en) * 1987-07-02 1988-11-22 The Procter & Gamble Company Calcium-iron mineral supplements

Also Published As

Publication number Publication date
CA1329774C (fr) 1994-05-24
EP0304986A2 (fr) 1989-03-01
JP2738541B2 (ja) 1998-04-08
EP0304986A3 (en) 1990-03-07
PH25585A (en) 1991-08-08
KR970009582B1 (en) 1997-06-14
JPH01151515A (ja) 1989-06-14
IE882609L (en) 1989-02-28
IE61451B1 (en) 1994-11-02
ATE88633T1 (de) 1993-05-15
DE3880587D1 (de) 1993-06-03
DE3880587T2 (de) 1993-09-23
KR890003390A (ko) 1989-04-14
EP0304986B1 (fr) 1993-04-28

Similar Documents

Publication Publication Date Title
US5128374A (en) Use of calcium citrate malate for the treatment of osteoporosis and related disorders
JP3708115B2 (ja) 混合カルシウム及びビタミンｄ補給品
EP0542912B1 (fr) Complements de calcium et de traces de mineraux
AU666654B2 (en) Calcium, trace mineral, vitamin D and drug therapy combinations
US5232709A (en) Calcium and trace mineral supplements comprising estrogen
EP0304987B1 (fr) Suppléments de calcium
HK1006149B (en) Calcium and trace mineral supplements
EP0304986B1 (fr) Utilisation de certains Calcium-Citrate-Malate pour l'obtention d'un médicament destiné au traitement de l'ostéoporose
US5314919A (en) Calcium supplements
US20040220266A1 (en) Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US5905093A (en) Fish scale extract as a calcium supplement
WO1999040941A1 (fr) Extrait d'ecailles de poissons utilise comme supplement calcique

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20080814